Vir Singh Negi

Vir Singh Negi

Auto-generated profile, based on publicly available information

Vir Singh Negi

Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research , Puducherry

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
SSSanket Shah
Sanket Shah
DDDebashish Danda
Debashish Danda
CKChengappa Kavadichanda
Chengappa Kavadichanda
SDSaibal Das
Saibal Das
MAM. B. Adarsh
M. B. Adarsh
VNVir Singh Negi
Vir Singh Negi

13 April 2020 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SSSanket Shah
Sanket Shah
SDSaibal Das
Saibal Das
AJAvinash Jain
Avinash Jain
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
VNVir Singh Negi
Vir Singh Negi
Objective The pandemic Coronavirus Disease‐19 (COVID‐19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID‐19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID‐19. Methods PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS‐CoV‐2 (pre‐clinical studies) or COVID‐19 (clinical studies) until 30 March 2020. The available literature was critically appraised. Results A total of 45 articles were screened and five (three in vitro pre‐clinical studies and two clinical opinions) were included. The pre‐clinical studies showed the prophylactic effects of CQ and HCQ against SARS‐CoV‐2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID‐19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID‐19 were available. Conclusion Although pre‐clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID‐19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID‐19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies.

13 June 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
GSGaurav Seth
Gaurav Seth
CKChengappa Kavadichanda
Chengappa Kavadichanda
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
RBRamesh Babu
Ramesh Babu
PBPooja Belani
Pooja Belani
VNVir Singh Negi
Vir Singh Negi

7 December 2020 in Rheumatology
Verified
Journal Article
Closed access
CKChengappa Kavadichanda
Chengappa Kavadichanda
SSSanket Shah
Sanket Shah
ADAnu Daber
Anu Daber
DBDevender Bairwa
Devender Bairwa
AMAnoop Mathew
Anoop Mathew
VNVir Singh Negi
Vir Singh Negi
Objectives: To assess acceptability of teleconsultation among the socioeconomically marginalized sections of patients with rheumatic and musculoskeletal diseases (RMDs), to identify the socioeconomic barriers in continuing rheumatology care during the COVID-19 crisis and to identify patients who could benefit by shifting to tele-rheumatology consultations. Methods: This was a cross sectional analytical study done at a tertiary care teaching hospital in India including patients with RMDs who were not on biological diseases modifying agents. Assessment of disease status, socioeconomic status and economic impact of COVID-19 was done via tele-consultation. Results: Out of the 680 patients satisfying inclusion criteria, 373 completed the study. The format was found easy by 334 (89.6%) of them and 284 (76.1%) considered tele-rheumatology better than in-person consultation. During the pre-COVID months, the median monthly per capita income of the families of our patients and cost of illness was Indian rupees (INR) 2000 (US$ 26) and INR 1685 (US$ 21.91), respectively. Families whose financial needs were met (OR = 0.38, 95% CI: 0.239, 0.598) or those with schooling upto at least secondary school (OR = 0.442, 95% CI: 0.260, 0.752) (P =0.002) were less likely to stop prescription drugs. In a hypothetical model, 289 (77.4%) could be successfully switched to tele-rheumatology follow-up. Conclusion: The acceptability of tele-rheumatology among socioeconomically marginalized patients with RMDs is good. During times of crisis, patients from poorer strata of society and lower educational background are likely to abruptly stop medications. Switching to a telemedicine-based hybrid model is likely to improve drug adherence with substantial savings on loss of pay and out of pocket expenditure.

23 August 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AJAnkit Jain
Ankit Jain
BSBheemanathi Hanuman Srinivas
Bheemanathi Hanuman Srinivas
DEDantis Emmanuel
Dantis Emmanuel
VJVikramraj K. Jain
Vikramraj K. Jain
SPSreejith Parameshwaran
Sreejith Parameshwaran
VNVir Singh Negi
Vir Singh Negi

14 October 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AJAvinash Jain
Avinash Jain
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
ASAman Sharma
Aman Sharma
AWAnupam Wakhlu
Anupam Wakhlu
VAVikas Agarwal
Vikas Agarwal
VNVir Singh Negi
Vir Singh Negi